Wake Forest University Health Sciences
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.
Primary Objective: • To measure Overall Response Rate to treatment with Cetuximab as single agent in patients with recurrent or metastatic head and neck squamous cell cancer who failed PD-1 inhibitors alone or in combination with chemotherapy. Secondary Objective(s): * Measure Duration of Response (DUR), Progression Free Survival and Overall Survival and for treatment with single agent Cetuximab after immunotherapy with PD-1 inhibitors in Head and Neck Squamous Cell Carcinoma. * Evaluate treatment toxicity with single agent Cetuximab in this patient population. OUTLINE: Patients receive ce…
Inclusion Criteria: * Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma. * Measurable disease by scans- at least one measurable lesion. * Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy. * Patients must have a Performance Status of 0-2. * Patients must be greater than or equal to 18 years old. * Participant is willing and able to comply with the protocol for the duration of the study. * Ability to understand and the willingness to sign an Institutional Review Board-…
A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation. The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed. The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab. Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment.
Ancillary studies
Ancillary studies
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.